During the treatment, losing my hair was upsetting, but I had bigger problems, like cancer and sepsis. The post-chemo hair ...

Q1 2025 Earnings Conference Call April 29, 2025 6:45 AM ETCompany ParticipantsAndy Barnett - Head of IRPascal Soriot ...

Results from phase 2 trials appear to support the use of chemotherapy-free regimens in patients with osimertinib-resistant ...

If you're an avid quilter like me, you're always looking for new quilt patterns — and we found a lot of great ones for summer 2025.

Houston has $141.5 million on the books for the 2025-26 campaign, and the projected salary cap is $154.6 million ... the highest priority among Houston's own free agents. From there, the ...

Now that Atlanta's 2024-25 campaign has officially ended, let's take a look at their looming salary cap situation, biggest pending contract decisions and potential free-agent targets. The good ...

NICE has backed Celgene’s Revlimid for routine NHS use in another indication, follicular lymphoma, as part of a chemotherapy-free regimen with Roche’s MabThera. The cost-effectiveness agency ...

Welcome to the Revolution Medicines Q1 2025 Earnings Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over ...